Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial

NCT06772376 is registered in ClinicalTrials.gov with Fuzhou General Hospital as lead sponsor.

NCT NCT06772376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06772376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial
Lead sponsor
Fuzhou General Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
June 1, 2026
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer in normal and malignant tumors